Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.
  • ArrayPharmacy
  • call for care 214.379.2700

    Choice Cancer Care is here for you 9AM – 5PM Monday – Friday

    Inquiring after hours? Complete our contact form and we will be in touch as soon as possible.


  • Patientportal

    Access Your Portal To Health at Choice Cancer Care.

    Learn more about becoming a CCC Patient, including insurance information and patient rights, or login to access your personal portal for in-depth information about your health.

    LoginSign UpLearn More

  • Patientforms
  • get a second opinion

    Recent Diagnosis? Gain Confidence With A Second Opinion.

    Find out what to ask your doctor, what a second opinion could mean for you, and take the steps to get you on the right path to treat your cancer.

    Complete this form for a no obligation consultation:

    • certified

      Choice Cancer Care is proud to be recognized by the Quality Oncology Practice Initiative (QOPI®) for excellence in quality, and safety in the administration of cancer care.

      Learn More

    How PARP Treats Advanced Prostate Cancer

    The FDA has approved rucaparib as a treatment for men who have advanced prostate cancer with mutated BRCA1/BRCA2 genes.

    Prostate cancer is the number one cancer andthe second cause of cancer deaths among men in the USA. The mCRPC (metastatic, castrate-resistant prostate cancer) is incurable, but researchers are exploring possible treatment options.

    Rucaparib falls under the PARP (Poly ADP-ribose polymerase) inhibitors class. The anti-cancer drugs target cancer cells with weakness, especially on how they repair their damaged DNA. The drugs have been used to treat ovarian cancer, and some inherited types of pancreatic and breast cancer.

    mCRPC patients present poor outcomes when they use conventional treatment methods. Therefore, to treat patients with advanced prostate cancer, there needs to be personalized medicine. Twelve percent of patients with advanced prostate cancer have tumors with BRCA2/BRCA1 alteration. Therefore, the rucaparib FDA approval is exciting to patients, oncologists, and researchers.

    The objective of the TRITON2 PHASE II study was to find out if rucaparib can effectively and safely treat men with mCRPC due to their genetic profile. The study participants included men who had completed chemotherapy and hormone therapy. The participants were given 600mg of rucaparib two times a day. The prostate-specific antigen levels in more than half the patients improved.

    The researchers concluded that the anti-cancer drug had a similar safety profile with what they had experienced in other tumors. They, however, identified anemia as the most common side effect.

    Research is underway to establish test combinations of PARP inhibitors with other experimental or conventional therapies to increase the number of mCRPC patients that benefit from the PARP inhibitor.

    Patnaik, MD, Ph.D., and one of the research authors explains, “In a separate publication, we have demonstrated that additional non-BRCA1/2 mutations within the DNA repair pathway in mCRPC patients could confer sensitivity or resistance to PARP inhibitor rucaparib…. We still have a lot more to learn about which patients with additional genetically defined alterations in the DNA repair pathway will benefit most from this therapy.”



    Cancer Screening Guidelines

    Screening can help doctors discover and treat some types of cancer early. Usually, cancer treatment is more effective when the disease is detected in its early stages and there could be a better chance of curing the cancer. Some...

    Learn More

    Learn About Your Options

    Your journey with cancer is influenced by several factors. These factors include your overall condition, the specific characteristics of your cancer, and whether the goal of treatment is to eradicate your cancer, stop your cancer from spreading to other areas...

    Learn More